Key highlights
Achieved seamless Bluefield implementation
Enhanced real-time analytics and data quality
Ensured FDA-compliant processes with reduced risk
Overview
Zensar partnered with the client, a global biotech leader in vaccines and generics, to transition from SAP ECC to SAP S/4HANA using a Bluefield approach on the SAP RISE platform. Leveraging automation tools, the project ensured minimal business disruption, seamless data migration, and third-party integrations while maintaining strict FDA compliance and delivering real-time analytics for enhanced productivity.
Challenges
1.
Business
SAP ECC mainstream support is ending in 2027
2.
Business
Minimizing business disruption
3.
Business
Avoiding risks in processes as per FDA norms
4.
Business
Change management
5.
Technical
Standardization and optimization of business processes
6.
Technical
Legacy system complexity
7.
Technical
Data migration and integration
Solution
1.
Scope
Implementing SAP S/4HANA Cloud Private Edition (RISE with SAP)
2.
Approach
Bluefield implementation with selective data transition
3.
Approach
Key features include real-time analytics, improved data quality, and streamlined processes
4.
Approach
Synchronous bi-directional integration of the required third-party systems with the SAP S/4HANA system
Approach
Suggested best practices by SAP
Impact
Improved decision-making capabilities, productivity, and efficiency
Reduced business disruption
Faster implementation
Single IS Pharma (SAP S/4HANA) system-driven business process solution
Customer would be working on the latest/updated tool in the market, which recognizes FDA norms and quality processes
Zensar leveraged its tools and processes to reduce risk and increase productivity